AspenBio Pharma Announces Proposed Public Offering
CASTLE ROCK, Colo., Nov. 14, 2012
CASTLE ROCK, Colo., Nov. 14, 2012 /PRNewswire/ --AspenBio Pharma, Inc.
(Nasdaq: APPY), an in vitro diagnostic company, today announced its intention,
subject to market and other conditions, to commence a public offering of its
common stock.AspenBio intends to use the net proceeds from this offering for
general corporate purposes, including conducting a clinical trial for its
blood-based appendicitis test and for working capital purposes.
Aegis Capital Corp. is acting as the sole book-running manager for the
A registration statement on Form S-3 relating to the shares was filed with the
Securities and Exchange Commission and was declared effective on July 27,
2011. A preliminary prospectus supplement relating to the offering will be
filed with the SEC. When available, copies of the prospectus supplement and
the accompanying prospectus relating to these securities may be obtained from
the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue,
18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email:
email@example.com. Electronic copies of the prospectus supplement and
accompanying prospectus will also be available on the website of the SEC at
This press release does not constitute an offer to sell, or the solicitation
of an offer to buy, these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale is not permitted.
About AspenBio Pharma
AspenBio Pharma, Inc. is an in vitro diagnostic company focused on the
clinical development and commercialization of its blood-based appendicitis
test. The unique appendicitis test has projected high sensitivity and
negative predictive value and is designed to aid in the identification of
patients at low risk for acute appendicitis, allowing for more conservative
patient management. The test is being developed initially for pediatric,
adolescent and young adult patients with abdominal pain, as this population is
at the highest risk for appendicitis and has the highest risk of long-term
health effects associated with CT imaging. For more information, visit
This press release includes "forward-looking statements" of AspenBio Pharma,
Inc. ("AspenBio") as defined by the Securities and Exchange Commission
("SEC"). All statements, other than statements of historical fact, included in
this press release that address activities, events or developments that
AspenBio believes or anticipates will or may occur in the future are
forward-looking statements. These statements are based on certain assumptions
made based on experience, expected future developments and other factors
AspenBio believes are appropriate in the circumstances. Such statements are
subject to a number of assumptions, risks and uncertainties, many of which are
beyond the control of AspenBio. Investors are cautioned that any such
statements are not guarantees of future performance. Actual results or
developments may differ materially from those projected in the forward-looking
statements as a result of many factors, including our ability to successfully
complete required product development and modifications in a timely and cost
effective manner, complete clinical trial activities for AppyScore required
for FDA submission, obtain FDA clearance or approval, complete and obtain CE
Mark, cost effectively manufacture and generate revenues from AppyScore,
execute agreements required to successfully advance the company's objectives,
retain the management team to advance the products, overcome adverse changes
in market conditions and the regulatory environment, obtain and enforce
intellectual property rights, and realize value of intangible assets.
Furthermore, AspenBio does not intend (and is not obligated) to update
publicly any forward-looking statements. The contents of this press release
should be considered in conjunction with the risk factors contained in
AspenBio's recent filings with the SEC, including its Form 10-Q for the period
ended September 30, 2012, filed on November 7, 2012.
For Investors & Media:
Joshua Drumm, PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
SOURCE AspenBio Pharma, Inc.
Press spacebar to pause and continue. Press esc to stop.